Free Trial
NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis

Neoleukin Therapeutics logo
$23.09 +1.15 (+5.24%)
As of 07/23/2025

About Neoleukin Therapeutics Stock (NASDAQ:NLTX)

Key Stats

Today's Range
$22.26
$23.88
50-Day Range
$14.95
$23.09
52-Week Range
$2.03
$14.36
Volume
161,659 shs
Average Volume
50,104 shs
Market Capitalization
$217.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Stock News Headlines

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Why Elon put $51 million into this
A single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re quietly shipping 30 tons per year from a facility outside San Antonio.
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity
See More Headlines

NLTX Stock Analysis - Frequently Asked Questions

Neoleukin Therapeutics' stock was trading at $22.86 at the start of the year. Since then, NLTX stock has increased by 1.0% and is now trading at $23.09.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced its earnings results on Thursday, November, 4th. The company reported ($5.60) EPS for the quarter, hitting analysts' consensus estimates of ($5.60).

Neoleukin Therapeutics's stock reverse split on the morning of Tuesday, December 19th 2023.The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neoleukin Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), GE Aerospace (GE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/04/2021
Today
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NLTX
CIK
1404644
Employees
90
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.56 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-37.22%
Return on Assets
-30.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.33
Quick Ratio
15.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.08 per share
Price / Book
2.08

Miscellaneous

Outstanding Shares
9,398,000
Free Float
9,250,000
Market Cap
$217.00 million
Optionable
No Data
Beta
1.11
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:NLTX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners